China's Government-Backed BCI Push Could Bring Brain-Computer Tech to the Masses Within 3 to 5 Years | RC104

In this episode of Rebelliously Curious, host Chrissy Newton interviews Phoenix Peng, CEO and founder of Gestalt, a pioneering Chinese BCI company leveraging ultrasound technology. Peng shares his journey from internet entrepreneurship to leading cutting-edge neurotechnology, explaining why ultrasound—unlike electrical-based BCIs—offers non-invasive, whole-brain coverage with therapeutic potential for conditions like stroke rehabilitation, chronic pain, and mental illness. He contrasts China’s rapid clinical trial progress with the U.S.’s current edge in hardware precision, noting a 3–4 year gap in implantable device capabilities. While China leads in scale and speed of trials due to large populations and government support, Peng emphasizes that ethical oversight and global regulation are critical. He advocates for international collaboration through bodies like the UN to ensure BCI development prioritizes human agency over efficiency, and shares Gestalt’s manifesto centered on truth, long-term curiosity, and humanity-first innovation. The conversation underscores both the transformative promise and profound ethical challenges of mass-scale BCI deployment. Key takeaways include: 1) Ultrasound-based BCI enables non-invasive, large-scale brain interaction with therapeutic applications; 2) China is advancing rapidly in clinical trials but lags in hardware precision compared to the U.S.; 3) Ethical frameworks and global regulation are essential to prevent misuse and protect human agency; 4) Cross-border collaboration in science and ethics is vital for responsible innovation; 5) Companies must prioritize transparency and long-term human values over short-term gains; 6) The future of BCI lies not in surveillance but in healing and enhancing human potential; 7) Generational change and global cooperation will shape the ethical trajectory of neurotechnology; 8) A company’s manifesto can serve as a moral compass in high-stakes innovation.